Literature DB >> 15245330

Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue.

Lu Shan1, Thomas Marti, Ludvig M Sollid, Gary M Gray, Chaitan Khosla.   

Abstract

Prolyl endopeptidases have potential for treating coeliac sprue, a disease of the intestine caused by proteolytically resistant peptides from proline-rich prolamins of wheat, barley and rye. We compared the properties of three similar bacterial prolyl endopeptidases, including the known enzymes from Flavobacterium meningosepticum (FM) and Sphingomonas capsulate (SC) and a novel enzyme from Myxococcus xanthus (MX). These enzymes were interrogated with reference chromogenic substrates, as well as two related gluten peptides (PQPQLPYPQPQLP and LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF), believed to play a key role in coeliac sprue pathogenesis. In vitro and in vivo studies were conducted to evaluate the activity, specificity and acid/protease stability of the enzymes. All peptidases were relatively resistant to acid, pancreatic proteases and membrane peptidases of the small intestinal mucosa. Although their activities against reference substrates were similar, the enzymes exhibited substantial differences with respect to chain length and subsite specificity. SC hydrolysed PQPQLPYPQPQLP well, but had negligible activity against LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF. In contrast, the FM and MX peptidases cleaved both substrates, although the FM enzyme acted more rapidly on LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF than MX. Whereas the FM enzyme showed a preference for Pro-Gln bonds, SC cleaved both Pro-Gln and Pro-Tyr bonds with comparable efficiency, and MX had a modest preference for Pro-(Tyr/Phe) sites over Pro-Gln sites. While a more comprehensive understanding of sequence and chain-length specificity may be needed to assess the relative utility of alternative prolyl endopeptidases for treating coeliac sprue, our present work has illustrated the diverse nature of this class of enzymes from the standpoint of proteolysing complex substrates such as gluten.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15245330      PMCID: PMC1134072          DOI: 10.1042/BJ20040907

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  Catalysis of serine oligopeptidases is controlled by a gating filter mechanism.

Authors:  V Fülöp; Z Szeltner; L Polgár
Journal:  EMBO Rep       Date:  2000-09       Impact factor: 8.807

2.  In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope.

Authors:  R P Anderson; P Degano; A J Godkin; D P Jewell; A V Hill
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

3.  The noncatalytic beta-propeller domain of prolyl oligopeptidase enhances the catalytic capability of the peptidase domain.

Authors:  Z Szeltner; V Renner; L Polgár
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

Review 4.  The prolyl oligopeptidase family.

Authors:  L Polgár
Journal:  Cell Mol Life Sci       Date:  2002-02       Impact factor: 9.261

5.  Production of a panel of recombinant gliadins for the characterisation of T cell reactivity in coeliac disease.

Authors:  E H Arentz-Hansen; S N McAdam; O Molberg; C Kristiansen; L M Sollid
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

6.  Structures of prolyl oligopeptidase substrate/inhibitor complexes. Use of inhibitor binding for titration of the catalytic histidine residue.

Authors:  V Fülöp; Z Szeltner; V Renner; L Polgár
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

7.  The specificity of prolyl endopeptidase from Flavobacterium meningoseptum: mapping the S' subsites by positional scanning via acyl transfer.

Authors:  F Bordusa; H D Jakubke
Journal:  Bioorg Med Chem       Date:  1998-10       Impact factor: 3.641

8.  The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides.

Authors:  Willemijn Vader; Yvonne Kooy; Peter Van Veelen; Arnoud De Ru; Diana Harris; Willemien Benckhuijsen; Salvador Peña; Luisa Mearin; Jan Wouter Drijfhout; Frits Koning
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

9.  Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues.

Authors:  Helene Arentz-Hansen; Stephen N McAdam; Øyvind Molberg; Burkhard Fleckenstein; Knut E A Lundin; Thomas J D Jørgensen; Günther Jung; Peter Roepstorff; Ludvig M Sollid
Journal:  Gastroenterology       Date:  2002-09       Impact factor: 22.682

10.  Specificity of tissue transglutaminase explains cereal toxicity in celiac disease.

Authors:  L Willemijn Vader; Arnoud de Ru; Yvonne van der Wal; Yvonne M C Kooy; Willemien Benckhuijsen; M Luisa Mearin; Jan Wouter Drijfhout; Peter van Veelen; Frits Koning
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

View more
  61 in total

Review 1.  Targeted modification of wheat grain protein to reduce the content of celiac causing epitopes.

Authors:  C Osorio; N Wen; R Gemini; R Zemetra; D von Wettstein; S Rustgi
Journal:  Funct Integr Genomics       Date:  2012-06-26       Impact factor: 3.410

2.  Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes: diminishing toxic effects in intestinal epithelial cells.

Authors:  S M Stenman; K Lindfors; J I Venäläinen; A Hautala; P T Männistö; J A Garcia-Horsman; A Kaukovirta-Norja; S Auriola; T Mauriala; M Mäki; K Kaukinen
Journal:  Clin Exp Immunol       Date:  2010-06-15       Impact factor: 4.330

Review 3.  Celiac disease: pathogenesis of a model immunogenetic disease.

Authors:  Martin F Kagnoff
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

4.  Highly efficient gluten degradation by lactobacilli and fungal proteases during food processing: new perspectives for celiac disease.

Authors:  Carlo G Rizzello; Maria De Angelis; Raffaella Di Cagno; Alessandra Camarca; Marco Silano; Ilario Losito; Massimo De Vincenzi; Maria D De Bari; Francesco Palmisano; Francesco Maurano; Carmen Gianfrani; Marco Gobbetti
Journal:  Appl Environ Microbiol       Date:  2007-05-18       Impact factor: 4.792

Review 5.  Non-dietary forms of treatment for adult celiac disease.

Authors:  Hugh James Freeman
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06

6.  Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study.

Authors:  Greetje J Tack; Jolanda M W van de Water; Maaike J Bruins; Engelina M C Kooy-Winkelaar; Jeroen van Bergen; Petra Bonnet; Anita C E Vreugdenhil; Ilma Korponay-Szabo; Luppo Edens; B Mary E von Blomberg; Marco W J Schreurs; Chris J Mulder; Frits Koning
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

7.  Generation of food-grade recombinant Lactobacillus casei delivering Myxococcus xanthus prolyl endopeptidase.

Authors:  Patricia Alvarez-Sieiro; Maria Cruz Martin; Begoña Redruello; Beatriz Del Rio; Victor Ladero; Brad A Palanski; Chaitan Khosla; Maria Fernandez; Miguel A Alvarez
Journal:  Appl Microbiol Biotechnol       Date:  2014-04-22       Impact factor: 4.813

Review 8.  Biosynthetic Proteases That Catalyze the Macrocyclization of Ribosomally Synthesized Linear Peptides.

Authors:  Chayanid Ongpipattanakul; Satish K Nair
Journal:  Biochemistry       Date:  2018-03-27       Impact factor: 3.162

9.  Presence of celiac disease epitopes in modern and old hexaploid wheat varieties: wheat breeding may have contributed to increased prevalence of celiac disease.

Authors:  Hetty C van den Broeck; Hein C de Jong; Elma M J Salentijn; Liesbeth Dekking; Dirk Bosch; Rob J Hamer; Ludovicus J W J Gilissen; Ingrid M van der Meer; Marinus J M Smulders
Journal:  Theor Appl Genet       Date:  2010-07-28       Impact factor: 5.699

10.  A food-grade enzyme preparation with modest gluten detoxification properties.

Authors:  Jennifer Ehren; Belen Morón; Edith Martin; Michael T Bethune; Gary M Gray; Chaitan Khosla
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.